Ingredient name record

Ectoin

Evidence at a glance

1official function labelsIngredient context 2selected human studiesNot a full review

0selected legal receiptsNot a compliance verdict

Evidence coverage, not an efficacy or safety score.

Identity & coverage details

Official CosIng inventory context recorded; chemical identity and the complete current regulatory profile remain unverified; selected human studies available.

Recorded presence is not a safety rating, recommended dose or benefit claim.

Identity and formulation context

Names are indexed using case and whitespace normalization. Botanical, chemical and marketing identities have not been independently equated.

The publications use the spelling ectoine. These cream studies address atopic dermatitis, not general cosmetic efficacy. The pediatric formulation also contains hyaluronic acid; no effect is assigned to Ectoin alone or to Hydroxyectoin.

Functions listed by CosIng

SKIN CONDITIONING

Inventory functions describe the ingredient entry, not a finished product’s effects.

How this inventory match is used

The European Commission’s CosIng inventory is informational. An entry is not permission to use an ingredient or a safety assessment. Listed functions describe the inventory entry; they do not establish a finished product’s effects. The match uses the exact ingredient name, with case and whitespace normalization.

ECTOIN · Inventory identifiers

Inventory record: 56122 · Active
CAS identifiers in this entry: 96702-03-3
EC identifiers in this entry: Not listed

Checked 2026-10-02 · Read the official CosIng entry

Human study context

Primary publications checked 2026-10-03. These are selected studies, not a systematic review, safety rating or instructions for using a product.

A randomized, observer-blind, vehicle-control, multi-center clinical investigation for assessing the efficacy and tolerability of a 1% ectoine and hyaluronic acid 0.1%-containing medical device in pediatric patients with mild-to-moderate atopic dermatitis.

2023 · Original abstract reviewed

Material tested: 1% ectoine plus 0.1% hyaluronic acid medical-device cream versus vehicle.
Study design: Randomized observer-blind multicenter vehicle-controlled trial.
Participants: 70 children aged 2–18 randomized; 57 in the final analysis.
Concentration and schedule in the study: Twice daily for four weeks.
What the authors reported: Clinical scores favored the combination at day 28. Mild cutaneous events were reported in eight active-treatment patients and two vehicle patients.

What this does not establish

Combination does not isolate ectoine; 13 randomized participants absent from final analysis.
Disease-specific pediatric findings do not establish routine cosmetic outcomes. Publication 2023; electronic publication 2022. PubMed lists BODERM SA funding.

Read the original publication

Ectoine-containing cream in the treatment of mild to moderate atopic dermatitis: a randomised, comparator-controlled, intra-individual double-blind, multi-center trial.

2014 · Original abstract reviewed

Material tested: EHK02-01 ectoine-containing cream versus a nonsteroidal anti-inflammatory reference cream; concentration absent from the abstract.
Study design: Randomized intra-individual double-blind multicenter active-comparator trial.
Participants: 65 adults aged 18–65 with mild-to-moderate atopic dermatitis.
Concentration and schedule in the study: Both creams on symmetrical lesions twice daily for 28 days.
What the authors reported: Authors reported similar clinical efficacy to the reference and good observed tolerability.

What this does not establish

No vehicle-only arm; concentration and full formulation are absent from the abstract.
Reported equivalence and tolerability are confined to this selected trial, not universal safety.

Read the original publication

Still unverified

Selected primary abstracts only, not a systematic review or a complete scientific profile.
Test preparations have not been matched to any Treatfolio product, market, batch or package.
Study schedules are not consumer instructions; regulatory status and personal suitability require separate evidence.
Chemical identity, the complete current regulatory profile and finished-product effects remain unverified.